UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Male | Melanoma - pathology | CTLA-4 Antigen - immunology | Drug-Related Side Effects and Adverse Reactions - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | CTLA-4 Antigen - therapeutic use | Neoplasm Staging | Paclitaxel - administration & dosage | Medical colleges | Care and treatment | Chemotherapy | Immunotherapy | Immunoglobulin G | Melanoma | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1558 - 1568
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Double-Blind Method | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Nivolumab | Mutation | Melanoma - mortality | Viral antibodies | Medical colleges | Care and treatment | Patient outcomes | Melanoma | Antibodies | Clinical trials | Analysis | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - immunology | Kaplan-Meier Estimate | Treatment Outcome | Melanoma - pathology | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - immunology | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Aged | Melanoma - mortality | Chemotherapy | Hospitals | Melanoma | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9948, pp. 1109 - 1117
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Public health. Hygiene-occupational medicine | Public health. Hygiene | General aspects | Miscellaneous | Dermatology | Biological and medical sciences | Medical sciences | Drug Eruptions - etiology | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Adolescent | Adult | Female | Aged | Pruritus - chemically induced | Dose-response relationship (Biochemistry) | Pharmacology, Experimental | Research | Drug therapy | Melanoma | Antigens | Cytotoxicity | Metastasis | Kinases | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
5.
Full Text
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 459 - 465
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - pathology | Prospective Studies | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Melanoma - secondary | Brain Neoplasms - secondary | Melanoma - drug therapy | Adult | Female | Aged | Care and treatment | Metastasis | Research | Oncology, Experimental | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. e143 - e152
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | UNTREATED MELANOMA | CARBOPLATIN | PEMBROLIZUMAB | SOLID TUMORS | IMMUNE-RELATED RESPONSE | DOUBLE-BLIND | NIVOLUMAB | COMBINATION | IPILIMUMAB | Life Sciences & Biomedicine | Oncology | Science & Technology | Neoplasms - therapy | Practice Guidelines as Topic - standards | Humans | Immunotherapy | Response Evaluation Criteria in Solid Tumors | Tumor Burden | Disease Progression | Usage | Chemotherapy | Oncology, Experimental | Analysis | Research | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 943 - 955
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - pathology | Prognosis | Skin Neoplasms - drug therapy | Drug Administration Schedule | Follow-Up Studies | Humans | Ipilimumab | Middle Aged | Male | Survival Rate | Melanoma - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Female | Aged | Neoplasm Staging | Complications and side effects | Medical colleges | Research institutes | Melanoma | Analysis | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. e270 - e278
Hematology, Oncology and Palliative Medicine | GAMMA-KNIFE RADIOSURGERY | BREAST-CANCER | VOLUMETRIC DATA ERRORS | SOLID TUMORS | CLINICAL-TRIALS | GUIDELINES | PHASE-II | Life Sciences & Biomedicine | Oncology | Science & Technology | Magnetic Resonance Imaging | Brain Neoplasms - secondary | Glioma - secondary | Glioma - pathology | Humans | Brain Neoplasms - pathology | Central Nervous System - pathology | Clinical Trials as Topic | Glioma - epidemiology | Brain Neoplasms - epidemiology | Metastasis | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. e407 - e416
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Brain Neoplasms - secondary | Brain Neoplasms - psychology | Humans | Quality of Life | Clinical Trials as Topic | Cognition | Research Design | Clinical trials | Reports | Metastasis | Brain tumors | Index Medicus
Journal Article